Ginkgo Bioworks Holdings Net Cash Flow 2020-2025 | DNA

Ginkgo Bioworks Holdings net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Ginkgo Bioworks Holdings Net Cash Flow 2020-2025 | DNA

Ginkgo Bioworks Holdings net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.5B
Amgen (AMGN)$165.9B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$99.6B
CSL (CSLLY)$86.2B
GSK (GSK)$78.3B
Regeneron Pharmaceuticals (REGN)$61B
Alnylam Pharmaceuticals (ALNY)$42.8B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.4B
Illumina (ILMN)$17B
Genmab (GMAB)$15.2B
Genmab (GNMSF)$14.9B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.5B
QIAGEN (QGEN)$11.4B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.2B
Bio-Techne Corp (TECH)$9.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B